Last reviewed 2026-04-20 · How we verify

Demycin (BUCLOSAMIDE)

Phase 2 active Small molecule

Demycin (generic name: BUCLOSAMIDE) is a buclosamide drug. It is currently in Phase 2 development.

Demycin works by interacting with a specific cellular target to modulate its activity.

Demycin, also known as buclosamide, is a small molecule drug in the buclosamide class. Its exact target is unknown, but it is used to treat certain conditions. Demycin's commercial status is unclear, and it may be patented or have generic manufacturers. Key safety considerations are not well-documented. Further research is needed to fully understand Demycin's properties and uses.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BUCLOSAMIDE
Drug class	buclosamide
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your cells are like a orchestra, and Demycin is a conductor that helps the different sections work together in harmony. By adjusting the way these cellular components communicate, Demycin can help restore balance and alleviate symptoms. This process is complex and involves many molecular interactions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Demycin CI brief — competitive landscape report
Demycin updates RSS · CI watch RSS

Frequently asked questions about Demycin

What is Demycin?

Demycin (BUCLOSAMIDE) is a buclosamide drug.

How does Demycin work?

Demycin works by interacting with a specific cellular target to modulate its activity.

What is the generic name of Demycin?

BUCLOSAMIDE is the generic (nonproprietary) name of Demycin.

What drug class is Demycin in?

Demycin belongs to the buclosamide class. See all buclosamide drugs at /class/buclosamide.

What development phase is Demycin in?

Demycin is in Phase 2.

Drug class: All buclosamide drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing